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Results

DNMT3A is expressed in presumptive otic region and otic placode
As a first step in examining the possible relationship between DNMT3A and placode development, we performed in situ hybridization at gastrula through neurula stages to determine its expression pattern relative to that of ear precursors (dashed lines in Fig. 1 ). We find that DNMT3A is expressed in the neural plate border at HH4 (Fig. 1A) . While high expression continues in the neural plate, as previously shown (Hu et al., 2012), DNMT3A also is expressed laterally in the presumptive ear territory at HH6 (Fig. 1B) and HH8 (Fig. 1C) . Transverse sections reveal that expression is elevated in the ectodermal layer at the stages examined ( Knock down of DNMT3A caused a down-regulation of the otic placode marker Gbx2 very early in the process of placode specification, by HH7 ( Fig. 2A, A'). At HH9 Gbx2 was markedly down-regulated in the DNMT3A MO treated side (Fig. 2B, B', D) . Similar results were obtained for Pax2, another otic placode marker, at HH10 (Fig. 2E, E', F) .
We also noted down-regulation of Sox10 at HH11 after initiation of its expression in the otic placode (Fig. S1A, B) , similar to its effects on Sox10 expression in the neural crest (Hu et al., 2012), and otic expression of Soho1 at HH12 (Fig S1C) upon DNMT3A MO treatment. Interestingly, DNMT3A MO knockdown did not alter the expression of the epidermal marker Ck19 in the otic region (Fig 2G, G' ).
The early effects on gene expression led to subsequent defects in otic development as evidenced by a reduced size of the otic vesicle (Fig. 2C) . By the time that the morpholino was introduced at HH4, DNMT3A is already expressed. Thus, it is likely that some DNMT3A activity persists in the treated embryos due to perdurance of already translated protein and stability of resulting DNA methylation, likely explaining the semi-penetrant effects on otic vesicle formation.
To control for the specificity of the DNMT3A morpholino and demonstrate that the observed phenotype was not due to off-target effects, we coelectroporated the DNMT3A MO with a construct encoding ubiquitously expressed DNMT3A. This resulted in a marked rescue of the loss of function phenotype and restored Gbx2 expression (Fig. 3A, B, D) . Over-expression of the DNMT3A rescue construct alone did not alter Gbx2 expression (Fig. 3C ).
Altogether these results suggest that DNMT3A is critical for epigenetic Mutual repression between Gbx2 and Otx2 has been reported in sensory placode formation (Steventon et al., 2012 ). Therefore we also tested whether DNMT3A knock down causes an expansion of Otx2 expression at the expense of Gbx2. However, the results revealed no change in Otx2 expression (Fig. 5A) .
Similarly, expression of Sox2 and Sox3, previously shown to be direct targets of DNMT3A during neural crest formation (Hu et al., 2012), were unaffected in the otic placodal domain at HH9 (Fig. 5B, C) . 
